Lakefront Biotherapeutics NV (GLPGF)

Market Cap	1.92B -13.5%
Revenue (ttm)	1.13B +259.4%
Net Income	681.64M
EPS	10.34
Shares Out	n/a
PE Ratio	2.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	31.95
Previous Close	31.95
Day's Range	31.95 - 31.95
52-Week Range	26.24 - 34.00
Beta	0.12
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About GLPGF

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 196
• Stock Exchange: OTCMKTS
• Ticker Symbol: GLPGF

Financial Performance

In 2025, GLPGF's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error